Sanofi–Organobalance: yeast technology, 201201– license excl for vaccine production of modified S. cerevisiae strain to Sanofi Pasteur

	Period	2012-01-11
	Partner, 1st	Sanofi Pasteur (Group)
	Group	Sanofi (Group) [since May 2011]
	Partner, 2nd	Organobalance GmbH
	Product	recombinant protein production in yeast cells
	Product 2	vaccine

Organobalance GmbH. (1/11/12). "Press Release: Organobalance Signs Licensing Agreement with Sanofi Pasteur. Modified Strain of Yeast Paves Way for New Industrial Vaccine Production Process". Berlin.

The company ORGANOBALANCE GmbH, Berlin, Germany, today announced the conclusion of a licensing agreement with Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). This will provide Sanofi Pasteur with access to a modified yeast strain (Saccharomyces cerevisiae, more commonly known as baker's yeast) for use in vaccines. By signing the agreement, ORGANOBALANCE is granting Sanofi Pasteur exclusive rights to use of the modified yeast strain in the production of vaccines.

Prof. Christine Lang, Managing Director of ORGANOBALANCE GmbH, sees the licensing agreement as a further milestone for the company: "The modified form of Saccharomyces cerevisiae, both developed and patented by our company, is just one example of the farreaching expertise ORGANOBALANCE has to offer in the field of metabolic engineering. By making this agreement, we are strengthening our outstanding position in microbial strain development and the application of yeasts in industrial biotechnology. We are delighted to have made this agreement with Sanofi Pasteur, a partner who will make commercial use of our research findings on an industrial scale."

About ORGANOBALANCE:

ORGANOBALANCE GmbH is a company specialising in microbiological strain development. ORGANOBALANCE targets the use of Saccharomyces cerevisiae yeast strains for synthesising materials which can be applied in the processes of industrial and pharmaceutical biotechnology. The company also focuses on tapping the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out the microflora and restore the microbial equilibrium in a natural way. By drawing on its own collection of microorganisms suitable for use in foodstuffs, as well as its own OASSYS® screening systems, ORGANOBALANCE develops new biological products in the areas of pharmaceutics, preventive healthcare, nutrition and cosmetics. ORGANOBALANCE was founded in 2001 and is based in Berlin, Germany. More information can be found at http://www.organobalance.com.

Further information:

ORGANOBALANCE GmbH
Gustav-Meyer-Allee 25
13355 Berlin
Germany
Tel.: +49 30 46307-200
Fax: +49 30 46307-210
Email: info@organobalance.com
Internet: http://www.organobalance.com

Press contact:

COMAGO
Communication . Marketing . Organisation
Helmut Landenberger
Wiesenstraße 55
14612 Falkensee
Germany
Tel.: +49 33 22 84 06 52
Fax: +49 33 22 84 06 53
Email: mail@comago.de
Internet: http://www.comago.de

Record changed: 2012-02-05

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Sanofi–Organobalance: yeast technology, 201201– license excl for vaccine production of modified S. cerevisiae strain to Sanofi Pasteur

Organobalance GmbH. (1/11/12). "Press Release: Organobalance Signs Licensing Agreement with Sanofi Pasteur. Modified Strain of Yeast Paves Way for New Industrial Vaccine Production Process". Berlin.

More documents for Sanofi (Group) [since May 2011]